<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281021</url>
  </required_header>
  <id_info>
    <org_study_id>629.05</org_study_id>
    <secondary_id>BCC-LUN-05-001</secondary_id>
    <nct_id>NCT00281021</nct_id>
  </id_info>
  <brief_title>Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Trial of Second Line Erlotinib + Digoxin in Patients With Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James Graham Brown Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the potential benefit of adding Digoxin to&#xD;
      erlotinib (Tarceva) treatment for patients with non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancer cases. The majority of&#xD;
      NSCLC patients have advanced disease at the time of diagnosis, which usually requires&#xD;
      treatment beyond standard first-line chemotherapy. Until recently, patients were limited in&#xD;
      the number of options available for second-line treatment of NSCLC. In 2004, erlotinib was&#xD;
      approved by the FDA for second and third-line treatment of NSCLC. Erlotinib is a cancer&#xD;
      chemotherapy medication that slows the growth and spread of cancer cells in the body.&#xD;
&#xD;
      Recent research suggests that a medication called Digoxin can sensitize cancer cells to&#xD;
      respond better to chemotherapy. Digoxin is normally used to treat certain heart conditions by&#xD;
      helping the heart beat more strongly and regularly and is not approved by the FDA for the&#xD;
      treatment of NSCLC. Investigators hope that subject response rates to standard erlotinib&#xD;
      therapy will be significantly improved by the addition of Digoxin.&#xD;
&#xD;
      The purpose of this study is to determine the tumor response rate and overall survival of&#xD;
      patients with non-small cell lung cancer treated with a daily regimen of erlotinib (Tarceva)&#xD;
      plus Digoxin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis revealed that only 1 patient had a partial response.&#xD;
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest &amp; Abdomen.</measure>
    <time_frame>Measured every 6 weeks after baseline until disease progression, an average of 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Carcinoma, Non-Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>Erlotinib and Digoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib plus Digoxin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib plus Digoxin</intervention_name>
    <description>Each subject will receive erlotinib and digoxin daily until progression.</description>
    <arm_group_label>Erlotinib and Digoxin</arm_group_label>
    <other_name>Tarceva</other_name>
    <other_name>Digitalis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of non-small cell lung cancer&#xD;
&#xD;
          -  measurable or evaluable disease&#xD;
&#xD;
          -  primary tumor must be documented by histopathic analysis&#xD;
&#xD;
          -  disease recurrences occurring greater than five years after original diagnosis must be&#xD;
             biopsy proven&#xD;
&#xD;
          -  treatment with only one prior chemotherapy regimen for advanced disease (one&#xD;
             additional prior regimen was allowed for neoadjuvant, adjuvant, or neoadjuvant plus&#xD;
             adjuvant therapy)&#xD;
&#xD;
          -  serum creatinine &lt; 2mg/dl, or a calculated creatinine clearance &gt; 40cc/min using the&#xD;
             following formula: (140-age) x WT(kg) x 0.85 (if female 0.72) x creatinine (mg/dl).&#xD;
             Tests must be done within 28 days prior to registration&#xD;
&#xD;
          -  must have a CT scan (chest &amp; abdomen) within 4 weeks prior to registration&#xD;
&#xD;
          -  Zubrod performance status of 0-3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women who are pregnant or nursing&#xD;
&#xD;
          -  no other prior malignancy is allowed except for: adequately treated basal cell or&#xD;
             squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II&#xD;
             cancer from which the patient is currently in complete remission, or any other cancer&#xD;
             from which the patient has been disease-free for 5 years&#xD;
&#xD;
          -  history of ventricular fibrillation, sinus node or AV nodal disease, Wolff Parkinson&#xD;
             White Syndrome, evidence of congestive heart failure, chest pain with exertion,&#xD;
             hemodynamically significant or life threatening cardiac arrhythmia, or evidence of&#xD;
             prior myocardial infarction on EKG. EKG must have been done within 28 days prior to&#xD;
             registration. A normal cardiac stress test within 182 days prior to registration is&#xD;
             required for all patients over 50 years old or those with abnormal EKG or any history&#xD;
             of cardiac disease.&#xD;
&#xD;
          -  hypersensitivity to erlotinib and/or Digoxin&#xD;
&#xD;
          -  abnormal levels of K, Mg, and/or Ca, or conditions which cause such abnormalities&#xD;
             (e.g. malnutrition, severe diarrhea, prolonged vomiting, dialysis, GI suction,&#xD;
             untreated hypothyroidism, and use of diuretics, amphotericin B, steroids, or antacids)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goetz H Kloecker, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>James Graham Brown Cancer Center/ University of Louisville</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.browncancercenter.org</url>
    <description>James Graham Brown Cancer Center</description>
  </link>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>January 23, 2006</study_first_submitted>
  <study_first_submitted_qc>January 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2006</study_first_posted>
  <results_first_submitted>April 12, 2013</results_first_submitted>
  <results_first_submitted_qc>November 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 10, 2014</results_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Goetz Kloecker</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Digoxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient accrual lasted from March 2006 until August 2008 and was stopped early at the time of interim analysis. 24 who completed at least 6 weeks of therapy are presented here.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Erlotinib and Digoxin</title>
          <description>Erlotinib plus Digoxin&#xD;
Erlotinib plus Digoxin : Each subject will receive erlotinib and digoxin daily until progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erlotinib and Digoxin</title>
          <description>Erlotinib plus Digoxin&#xD;
Erlotinib plus Digoxin : Each subject will receive erlotinib and digoxin daily until progression.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="34" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest &amp; Abdomen.</title>
        <time_frame>Measured every 6 weeks after baseline until disease progression, an average of 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib and Digoxin</title>
            <description>Erlotinib plus Digoxin&#xD;
Erlotinib plus Digoxin : Each subject will receive erlotinib and digoxin daily until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest &amp; Abdomen.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Erlotinib and Digoxin</title>
          <description>Erlotinib plus Digoxin&#xD;
Erlotinib plus Digoxin : Each subject will receive erlotinib and digoxin daily until progression.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Goetz Kloecker</name_or_title>
      <organization>James Graham Brown Cancer Center, University of Louisville</organization>
      <phone>502-562-4358</phone>
      <email>ghkloe01@exchange.louisville.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

